Will Increased Expenses Affect Bristol Myers' Performance?

Bristol Myers Squibb (BMY) has entered a $3.5 billion strategic collaboration with BioNTech for the co-development of the bispecific antibody BNT327, with an estimated $1.5 billion in acquired IPR&D expense likely impacting BMY's Q2 bottom line. This significant investment occurs as BMY faces existing revenue headwinds from generic erosion of drugs like Revlimid and Eliquis's Medicare Part D redesign, alongside intensifying competition in the dual-target cancer therapy space. The financial pressures have contributed to BMY's shares declining 15% year-to-date and recent downward revisions to its 2025 and 2026 EPS estimates, despite the stock trading at a discount to the large-cap pharma industry.

Analysis

Bristol Myers Squibb (BMY) is undertaking a significant strategic pivot with its $3.5 billion collaboration with BioNTech (BNTX) for the co-development of the bispecific antibody BNT327. This move, while aimed at strengthening its long-term oncology pipeline, introduces substantial near-term financial pressure. An immediate $1.5 billion in-process research and development (IPR&D) expense is expected to adversely impact Q2 bottom-line results. This significant cash outlay occurs while BMY already faces considerable top-line headwinds, including generic erosion for key drugs like Revlimid and Pomalyst, and pricing pressure on Eliquis due to the Medicare Part D redesign. Furthermore, the investment enters a highly competitive dual-target cancer therapy space, with both Merck (MRK) and Pfizer (PFE) recently securing similar assets, intensifying the execution risk. This confluence of factors has contributed to the stock's 15% year-to-date decline, starkly underperforming the industry's 1.3% growth. Despite this, BMY trades at a notable discount, with a forward P/E ratio of 7.40x compared to the industry average of 14.79x, although analyst estimates for 2025 and 2026 EPS have been revised downward, reflecting the market's cautious outlook.

Key Decisions for Investors

• Investors should anticipate continued near-term pressure on BMY's stock price due to the immediate $1.5 billion expense impacting Q2 earnings and ongoing revenue challenges from its legacy portfolio.
• For value-focused investors, the stock's discounted valuation at 7.40x forward earnings may represent a potential entry point, but this thesis is heavily dependent on the long-term success of the BNT327 pipeline asset.
• It is critical to monitor the competitive landscape, particularly clinical trial progress from Merck and Pfizer's rival bispecific antibody programs, as their success or failure will directly influence the future value of BMY's investment.
• Consider holding positions with caution, watching for management commentary on mitigating the impact of generic competition and any early clinical data from the BioNTech collaboration as key potential catalysts.